Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck (NCT05108090)

🧪 Interventions in This Study

• sentinel lymph node biopsy (SLNB) (PROCEDURE)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patients ≥ 18 years old at the time of informed consent
2. Ability to provide written informed consent and HIPAA authorization
3. Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging
4. Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)
5. Able to undergo general anesthesia for sentinel lymph node biopsy
6. Able to undergo CT scan with contrast or MRI with contrast
7. Undergo surgical resection (Moh's or micrographic resection or standard excision with sentinel lymph node biopsy) within 8 weeks of imaging

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Indiana University Melvin & Bren Simon Cancer Center — Indianapolis, Indiana

📞 Contact the Study Coordinator

Phone: (317) 529-6883

Email: ayekinn@iu.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Squamous Cell Carcinoma

• Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). — Houston, Texas
• Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design — Pittsburgh, Pennsylvania
• Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC — Tampa, Florida
• Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. — Victor, New York
• 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck — Baltimore, Maryland

Explore by condition: All Squamous Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.